THE RELATIONSHIP BETWEEN SERUM CALPROTECTIN AND PERIPHERAL NEUROPATHY IN A SAMPLE OF EGYPTIAN TYPE 2 DIABETIC PATIENTS | ||||
Ain Shams Medical Journal | ||||
Article 15, Volume 73, Issue 1, March 2022, Page 153-169 PDF (1011.95 K) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/asmj.2022.233552 | ||||
View on SCiNiTO | ||||
Authors | ||||
Marwa Adel Afify1; Salwa Seddik Hosny El Khawaga2; Nahla Nader Adly2; Mohamed Ali Awadein1; Ahmed Mohamed Bahaa El Din2 | ||||
1Internal Medicine Department, Misr University for Science and Technology, Egypt. | ||||
2Internal Medicine, Endocrinology & Metabolism Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. | ||||
Abstract | ||||
Background: Plasma calprotectin is a persistent biomarker of insulin resistance (IR), gastroenteritis, and cardiovascular disease (CVD). Elevated plasma levels of calprotectin have been reported in a variety of chronic inflammatory conditions. Elevated calprotectin levels have been reported to predict microvascular alterations in type 2 diabetic patients. Aim of the Work: To evaluate if there is a relationship between serum calprotectin and peripheral neuropathy in type 2 Diabetic patients. Patients and methods: This study is a case–control study that was conducted on 60 subjects their age range 45- 60 years old, divided into 3 groups underwent full clinical , neurological assessment and laboratory tests including (s.calprotectin ,hs CRP, HbA1C,cholesterol and TGs ) Results: statistically significant higher in diabetic with peripheral neuropathy than diabetic without neuropathy and controls regarding HS CRP,S calprotectin,HbA1c, FbG,2hrpp. ROC curve shows best cut off point for S. calprotectin level between diabetic without neuropathy and diabetic with neuropathy was >3.01 with sensitivity of 55.0%, specificity of 90.0% and AUC of 72.6%. Significant positive correlation between s.calprotectin and (hs.crp , age, SBP,BMI , FbG, TGs) Conclusion: High levels of calprotectin detected in type 2 diabetic patients with peripheral neuropathy suggest that this molecule may have a role in pathogenesis of neuroinflammation among these patients. Serum calprotectin levels in the future may be used as potential markers of its presence, severity and progression of the diabetic peripheral neuropathy. Therapeutic strategies for blocking S100A9 and its activity are recently under development in inflammatory diseases. | ||||
Keywords | ||||
Calprotectin; Diabetes Mellitus; Neuroinflammation; Peripheral Neuropathy | ||||
Statistics Article View: 262 PDF Download: 234 |
||||